Sotio

MaveriX Oncology is a biotechnology company dedicated to the discovery, development, and commercialization of targeted small-molecule cancer chemo-immunotherapies. The company focuses on innovative approaches that utilize previously unexploited insights into cancer and immune cell metabolism within the tumor microenvironment, which are applicable across various cancer types. By bridging the therapeutic gap in cancer treatment, MaveriX aims to enable medical practitioners to selectively deliver the tumor cell-killing effects of chemotherapy while simultaneously eliciting a robust immune response. This dual mechanism has the potential to enhance treatment efficacy against a wide range of cancers.

Cytune is a private company developing a broad portfolio of novel immunotherapeutic agents to treat primarily cancer. Cytune’s hedge relies on a proprietary scientific breakthrough in immunology: effective form of a major human immunocytokine: trans-presentation mechanism of a critical immune factor: IL-15 Cytune’s proprietary most advanced proprietary compound, CYP 0150, is a human interleukin-15 uniquely linked to its effector. Cytune is further developing conjugated monoclonal antibodies linked to CYP 0150. Cytune was founded in 2007 and is managed by Dr. David Bechard, a successful serial biotech entrepreneur and Dr. Yannick Jacques, Director of Public Research at the Inserm (National Institute for Health and Medical Research)